biostudies-literatureMai QGuangdong Key Laboratory of Immune Regulation and ImmunotherapyBasic and Applied Basic Research Foundation of Guangdong ProvinceNational Natural Science Foundation of ChinaGuangdong Natural Science Foundation Outstanding Youth Project85https://www.ebi.ac.uk/biostudies/studies/S-EPMC11334566biostudies-literatureUnknown13(1)Epstein-Barr virus (EBV) related post-transplant lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT), for which no standard therapeutic means have been developed. Significant increase expression of natural killer group 2 member D ligands (NKG2DLs) was observed on B-lymphoblastoid cells of EBV-PTLD, indicating NKG2DLs as potential therapeutic targets for treatment of EBV-PTLD. In this study, the recombinant constructs of NKG2D CAR and IL-15/IL-15Rα-NKG2D CAR were generated with a retroviral vector and then transduced to human T cells to produce NKG2D CAR-T and IL-15/IL-15Rα-NKG2D CAR-T cells, respectively. B-lymphoblastoid cell lines (B-LCLs) and the xenografted mouse models wereExperimental hematology & oncologyEfficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder.PMC113345662022B15150200502022A1515110828823002522023A15151102362022B1212010009Deng SZeng QLi JLi CWang CFu YHuang LZhang LMai QZhang SPang YLi TZeng JXu XHe BXu YfalseEfficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder.Epstein-Barr virus (EBV) related post-transplant lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT), for which no standard therapeutic means have been developed. Significant increase expression of natural killer group 2 member D ligands (NKG2DLs) was observed on B-lymphoblastoid cells of EBV-PTLD, indicating NKG2DLs as potential therapeutic targets for treatment of EBV-PTLD. In this study, the recombinant constructs of NKG2D CAR and IL-15/IL-15Rα-NKG2D CAR were generated with a retroviral vector and then transduced to human T cells to produce NKG2D CAR-T and IL-15/IL-15Rα-NKG2D CAR-T cells, respectively. B-lymphoblastoid cell lines (B-LCLs) and the xenografted mouse models were2024-01-01T00:00:00Z2024 Aug2026-07-15T08:03:57.288Z2025-04-05T21:20:43.079ZS-EPMC113345663916063110.1186/s40164-024-00553-z